Medical device and MedTech insights, news, tips and more

Nevro’s Senza Omnia Spinal Cord Neurostimulation System Gains FDA Approval

November 12, 2019

logo_nevro-with-R-v3

Nevro Corp Omnia IPG and Programmer

Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for the Senza® Omnia Spinal Cord Stimulation (SCS) System. The Omnia system is the first and only SCS system designed to deliver Nevro’s proprietary HF10® therapy in addition to all other available SCS frequencies.

The Omnia system is comprised of three new components. The first is a new programmer that will make it easy for physicians to offer a wider array of waveforms across the full SCS frequency spectrum, either separately or paired together. The second element of the system is a redesigned patient remote that is smaller and more intuitive for patients to use and enhances their experience. The new remote supports greater programming capacity, allowing for the flexibility to expand on the HF10 algorithm by giving physicians the ability to provide additional waveforms. Lastly, the system comes with an updated and upgradeable implantable pulse generator. Unlike non-rechargeable systems, the Omnia system is designed to last over ten years no matter what stimulation profile is used, has conditional full body MRI approval and will be upgradeable to future waveforms and frequencies.

“We are excited to launch Nevro’s next-generation spinal cord stimulation system as we believe it will allow physicians to help even more patients,” said Keith Grossman, Chairman and CEO of Nevro. “The Omnia system was developed based on feedback from the pain community and has resulted in a product that Nevro is uniquely able to provide. Omnia not only offers HF10, the most studied therapy available in the market that physicians have provided to over 53,000 patients, but it also gives physicians access to all other SCS frequencies, either independently or paired with HF10. With Omnia, our goal is to provide physicians the peace of mind that when they implant the system, they will have the versatility needed to achieve the best possible outcomes for their patients.”

Other SCS systems on the market are limited to a frequency below 1500 hertz. Omnia delivers the widest range of frequencies of any SCS system, between 2 and 10,000 hertz. In addition to HF10, Omnia offers the most waveforms in a single product and can be programmed to provide waveforms independently or paired with HF10. The pairing of waveforms across frequency ranges enables dual mechanisms of action that no other system can offer.

“The FDA approval of Omnia to treat chronic pain reflects what I’ve seen firsthand in my practice: many people suffering from chronic pain need a versatile solution to treat the dynamic, and sometimes progressive, nature of pain,” said Kasra Amirdelfan, M.D., Director of Medical Research at IPM Medical Group in Walnut Creek, California. “With Omnia, we can now offer patients the proven advantages of HF10 therapy while still having access to all other SCS frequencies. The patient response in my practice during the recent limited evaluation period has been positive and I look forward to providing the Omnia system more broadly in my practice.”

See Full Press Release: Nevro – Nevro Announces U.S. Launch of Senza® Omnia™ Spinal Cord Stimulation System to Treat Chronic Pain


Written by: Nevro


Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?

Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.